HRS-4642 combo for first-line advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your pancreatic cancer is advanced (has spread or is locally advanced) and has the KRAS G12D mutation
- You have not received chemotherapy or other systemic therapy for advanced pancreatic cancer
- You are in good enough health to be active (ECOG score 0 or 1)
- Your blood counts and organ function (kidney, liver, heart) are within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
This trial tests a new drug (HRS-4642) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has spread. It may help shrink tumors and extend life.
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
This study tests a new drug that targets a common genetic change (RAS) in pancreatic cancer, combined with other treatments. It aims to see if this combination is safe and effective for people whose cancer has advanced despite prior therapy.
This trial tests a new drug combined with other treatments for advanced pancreatic cancer. It aims to see if the combination can help people whose cancer has a specific genetic change called RAS mutation.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
Hear when a new Metastatic Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.